Figure 2.

Radiolabelled oxoquinoline derivatives developed in a step‐by‐step optimisation of pharmacokinetic and metabolic properties.36, 37, 38, 39, 40, 41, 42 Affinities reported in the picture are those of the non‐radioactive analogues.